On the public citation graph

Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma

https://doi.org/10.18632/oncotarget.3751

0 signed · 69 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.28454openalex-snapshot

MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy

inferredcites →https://doi.org/10.1002/path.4268openalex-snapshot

Developing biomarkers to predict benefit from HGF / MET pathway inhibitors

inferredcites →https://doi.org/10.1016/j.ccr.2011.11.005openalex-snapshot

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

inferredcites →https://doi.org/10.1016/j.cllc.2012.05.009openalex-snapshot

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1016/j.ijrobp.2005.06.037openalex-snapshot

Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients

inferredcites →https://doi.org/10.1016/j.ijrobp.2010.03.024openalex-snapshot

How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?

inferredcites →https://doi.org/10.1016/j.semradonc.2012.03.008openalex-snapshot

Current Management of Nasopharyngeal Cancer

inferredcites →https://doi.org/10.1016/s0140-6736(05)66698-6openalex-snapshot

Nasopharyngeal carcinoma

inferredcites →https://doi.org/10.1016/s1097-2765(01)00261-1openalex-snapshot

Coupling Met to Specific Pathways Results in Distinct Developmental Outcomes

inferredcites →https://doi.org/10.1016/s1097-2765(02)00439-2openalex-snapshot

A Mechanism of Cell Survival

inferredcites →https://doi.org/10.1016/s1470-2045(14)70023-3openalex-snapshot

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

inferredcites →https://doi.org/10.1016/s1535-6108(02)00017-xopenalex-snapshot

A role for common fragile site induction in amplification of human oncogenes

inferredcites →https://doi.org/10.1038/339155a0openalex-snapshot

Tyrosine kinase receptor indistinguishable from the c-met protein

inferredcites →https://doi.org/10.1038/bjc.2012.237openalex-snapshot

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

inferredcites →https://doi.org/10.1038/ncb2257openalex-snapshot

A direct role for Met endocytosis in tumorigenesis

inferredcites →https://doi.org/10.1038/nm.2402openalex-snapshot

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

inferredcites →https://doi.org/10.1038/nm.2819openalex-snapshot

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

inferredcites →https://doi.org/10.1038/nrc3205openalex-snapshot

Targeting MET in cancer: rationale and progress

inferredcites →https://doi.org/10.1038/nrclinonc.2012.71openalex-snapshot

MET: a promising anticancer therapeutic target

inferredcites →https://doi.org/10.1038/nrd2530openalex-snapshot

Drug development of MET inhibitors: targeting oncogene addiction and expedience

inferredcites →https://doi.org/10.1038/nrm1261openalex-snapshot

Met, metastasis, motility and more

inferredcites →https://doi.org/10.1038/nrm3012openalex-snapshot

MET signalling: principles and functions in development, organ regeneration and cancer

inferredcites →https://doi.org/10.1046/j.1365-2273.2001.00449.xopenalex-snapshot

The aetiology of nasopharyngeal carcinoma

inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

inferredcites →https://doi.org/10.1073/pnas.0508776103openalex-snapshot

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

inferredcites →https://doi.org/10.1093/annonc/mdu507openalex-snapshot

A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

inferredcites →https://doi.org/10.1093/jnci/dji112openalex-snapshot

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-1836openalex-snapshot

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-0450openalex-snapshot

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-1293openalex-snapshot

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

inferredcites →https://doi.org/10.1200/jco.2007.14.8494openalex-snapshot

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

inferredcites →https://doi.org/10.1200/jco.2008.19.1635openalex-snapshot

Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

inferredcites →https://doi.org/10.1200/jco.2010.31.4286openalex-snapshot

CCND1 and MET Genomic Amplification During Malignant Transformation of a Giant Cell Tumor of Bone

inferredcites →https://doi.org/10.1200/jco.2011.35.4928openalex-snapshot

MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

inferredcites →https://doi.org/10.1200/jco.2011.36.7706openalex-snapshot

Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

inferredcites →https://doi.org/10.1200/jco.2011.37.7929openalex-snapshot

MET Signaling Pathway: A Rational Target for Cancer Therapy

inferredcites →https://doi.org/10.1200/jco.2011.40.3774openalex-snapshot

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

inferredcites →https://doi.org/10.1200/jco.2012.43.3383openalex-snapshot

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

inferredcites →https://doi.org/10.1200/jco.2012.43.9422openalex-snapshot

MET As a Possible Target for Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2012.47.4189openalex-snapshot

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1245/s10434-010-0922-6openalex-snapshot

Altered Expression of E-cadherin by Hepatocyte Growth Factor and Effect on the Prognosis of Nasopharyngeal Carcinoma

inferredcites →https://doi.org/10.1245/s10434-013-3355-1openalex-snapshot

MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas

inferredcites →https://doi.org/10.1371/journal.pone.0079137openalex-snapshot

c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis

inferredcites →https://doi.org/10.3322/caac.20107openalex-snapshot

Global cancer statistics

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4662549openalex-extracted

Design, Synthesis and Pharmacological Evaluation of Novel Thiazole-Based Peptide Like Molecules as C-Met Kinase Inhibitors and Anticancer Agents

inferred← citeshttps://doi.org/10.1002/hed.25655openalex-snapshot

Role of c‐Met expression on prognosis of head and neck cancer: A literature review and meta‐analysis

inferred← citeshttps://doi.org/10.1002/hed.26049openalex-snapshot

Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients

inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_6openalex-snapshot

Receptor Tyrosine Kinase c-MET: A Biomarker and Therapeutic Target in Cancer

inferred← citeshttps://doi.org/10.1016/b978-0-12-818168-3.00011-5openalex-snapshot

c-Met as a potential therapeutic target in triple negative breast cancer

inferred← citeshttps://doi.org/10.1016/j.bmc.2020.115555openalex-snapshot

Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.08.044openalex-snapshot

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.08.021openalex-snapshot

Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing

inferred← citeshttps://doi.org/10.1016/j.molstruc.2024.139074openalex-snapshot

Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents

inferred← citeshttps://doi.org/10.1016/j.tjog.2018.11.020openalex-snapshot

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer

inferred← citeshttps://doi.org/10.1038/s41388-018-0185-4openalex-snapshot

The multiple paths towards MET receptor addiction in cancer

inferred← citeshttps://doi.org/10.1038/s41388-018-0537-0openalex-snapshot

Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation

inferred← citeshttps://doi.org/10.1038/s41419-022-04686-zopenalex-snapshot

CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis

inferred← citeshttps://doi.org/10.1038/s41598-018-28672-8openalex-snapshot

Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis

inferred← citeshttps://doi.org/10.1097/mpa.0000000000000604openalex-snapshot

Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies

inferred← citeshttps://doi.org/10.1186/s12885-019-5450-6openalex-snapshot

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients

inferred← citeshttps://doi.org/10.1186/s13000-018-0733-9openalex-snapshot

MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases

inferred← citeshttps://doi.org/10.1186/s13046-016-0292-4openalex-snapshot

Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing

inferred← citeshttps://doi.org/10.1186/s13048-025-01903-zopenalex-snapshot

Mechanistic insights into c-Met rs368750834 mutation and a bifunctional CAR-T strategy for serous ovarian carcinoma

inferred← citeshttps://doi.org/10.18632/oncotarget.21303openalex-snapshot

Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review

inferred← citeshttps://doi.org/10.18632/oncotarget.23656openalex-snapshot

WITHDRAWN: A meta-analysis of c-Met expression in head and neck cancer

inferred← citeshttps://doi.org/10.3390/cells9020522openalex-snapshot

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

inferred← citeshttps://doi.org/10.70675/689dceb7zaef0z44e6zabc1z752ba1b92b33openalex-snapshot

Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

inferred← citeshttps://doi.org/10.70675/ea435494z4946z4d12za5f5zd338f77b537bopenalex-snapshot

Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

inferred← citeshttps://doi.org/10.7150/jca.16686openalex-snapshot

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.